neuromyelitis optica
Information
- Disease name
- neuromyelitis optica
- Disease ID
- DOID:8869
- Description
- "A central nervous system disease characterized by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis)." [url:http\://en.wikipedia.org/wiki/Neuromyelitis_optica, url:http\://rarediseases.org/rare-diseases/neuromyelitis-optica/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04201262 | Active, not recruiting | Phase 3 | An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD | December 13, 2019 | July 31, 2024 |
| NCT04614454 | Active, not recruiting | Phase 2 | High Frequency Impulse Therapy for Neuropathic Pain in NMOSD | June 7, 2021 | December 31, 2024 |
| NCT04629274 | Active, not recruiting | N/A | In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO | June 15, 2020 | February 28, 2025 |
| NCT00716066 | Active, not recruiting | Phase 2 | Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases | June 2008 | January 31, 2030 |
| NCT00445367 | Active, not recruiting | Biobank For MS And Other Demyelinating Diseases | May 2006 | October 2036 | |
| NCT01777412 | Completed | Phase 1 | Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations | June 2013 | May 2015 |
| NCT00304291 | Completed | Phase 4 | A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) | August 2001 | May 2004 |
| NCT02003144 | Completed | Phase 3 | An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients | January 12, 2015 | July 12, 2021 |
| NCT05155644 | Completed | Safety of Therapeutic Step-down in Neuromyelitis Optica | August 1, 2020 | December 31, 2021 | |
| NCT03766347 | Completed | Pediatric NMOSD Observational Study | February 1, 2018 | April 3, 2024 | |
| NCT03942952 | Completed | PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. | October 22, 2019 | June 30, 2023 | |
| NCT00904826 | Completed | Phase 1/Phase 2 | An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | April 2009 | December 2011 |
| NCT01500681 | Completed | Maintenance Plasma Exchange for Neuromyelitis Optica | June 2012 | July 9, 2015 | |
| NCT01759602 | Completed | Phase 1 | C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation | January 2013 | November 2013 |
| NCT03452176 | Completed | N/A | Scrambler Trial for Pain in NMOSD | February 21, 2018 | August 29, 2019 |
| NCT04202055 | Completed | Immunologic Biomarker Profile of Cerebrospinal Fluid | January 2, 2018 | August 31, 2019 | |
| NCT02166346 | Completed | Phase 2 | Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) | February 2014 | January 8, 2017 |
| NCT02276963 | Completed | Phase 1 | Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses | January 2016 | February 15, 2019 |
| NCT02283671 | Completed | Phase 1 | Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B | September 2015 | July 10, 2019 |
| NCT02865018 | Completed | Phase 1/Phase 2 | Neuromyelitis Optica (NMO) & Cetirizine | April 2014 | February 2016 |
| NCT03062579 | Completed | Phase 1/Phase 2 | A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD | February 1, 2017 | May 15, 2018 |
| NCT03350633 | Completed | Phase 2/Phase 3 | Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders | November 1, 2017 | September 1, 2019 |
| NCT00501748 | Completed | Phase 1 | Safety and Tolerability of Rituximab in Neuromyelitis Optica | January 2004 | December 2010 |
| NCT06118398 | Not yet recruiting | Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders | November 5, 2023 | May 5, 2025 | |
| NCT06398158 | Not yet recruiting | Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder | June 1, 2024 | June 30, 2027 | |
| NCT05566769 | Recruiting | N/A | Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD | November 3, 2023 | July 1, 2025 |
| NCT01623076 | Recruiting | The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders | June 2012 | June 2025 | |
| NCT03370965 | Recruiting | N/A | Optic Neuritis Differential Diagnosis Study | June 7, 2019 | June 2025 |
| NCT05356858 | Recruiting | Phase 2 | An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients | May 7, 2022 | October 2024 |
| NCT05403138 | Recruiting | Phase 2/Phase 3 | Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders | November 1, 2022 | October 1, 2024 |
| NCT05573711 | Recruiting | Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder | October 1, 2022 | September 1, 2023 | |
| NCT05828212 | Recruiting | Phase 1 | Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica | April 30, 2023 | April 30, 2026 |
| NCT05982925 | Recruiting | Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders | May 6, 2022 | May 1, 2030 | |
| NCT02398994 | Terminated | Phase 3 | A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis | March 2015 | March 2016 |
| NCT01339455 | Terminated | Phase 1/Phase 2 | Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica | March 2011 | March 2017 |
| NCT01892345 | Terminated | Phase 3 | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) | April 11, 2014 | July 17, 2018 |
| NCT04155424 | Terminated | Phase 2/Phase 3 | A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder | January 14, 2020 | July 31, 2023 |
| NCT01024985 | Unknown status | Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct | September 2009 | December 2011 | |
| NCT05070286 | Unknown status | Lifestyle Weight Management Program: Interviews and Stakeholder Meetings. | January 1, 2022 | December 31, 2022 | |
| NCT02021825 | Unknown status | Phase 4 | Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders | March 2009 | December 2015 |
| NCT05245344 | Unknown status | Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study | April 1, 2022 | October 31, 2023 | |
| NCT04601142 | Unknown status | Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism | October 31, 2020 | December 31, 2021 | |
| NCT03829566 | Withdrawn | Phase 2/Phase 3 | Autologous Transplant To End NMO Spectrum Disorder | November 2019 | November 28, 2025 |
| NCT04131673 | Withdrawn | MS and NMOSD in African-Americans | July 5, 2019 | December 31, 2023 | |
| NCT02087813 | Withdrawn | Phase 1 | Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses | March 2014 |
- Disase is a (Disease Ontology)
- DOID:0060004
- Cross Reference ID (Disease Ontology)
- EFO:0004256
- Cross Reference ID (Disease Ontology)
- GARD:6267
- Cross Reference ID (Disease Ontology)
- ICD10CM:G36.0
- Cross Reference ID (Disease Ontology)
- ICD9CM:341.0
- Cross Reference ID (Disease Ontology)
- MESH:D009471
- Cross Reference ID (Disease Ontology)
- NCI:C84934
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:25044007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0027873
- Exact Synonym (Disease Ontology)
- Devic's disease
- Exact Synonym (Disease Ontology)
- Devic's syndrome
- OrphaNumber from OrphaNet (Orphanet)
- 71211
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009471